US FDA’s Reclassification Of Certain Drugs As Devices May Be 'Seismic Event' For Some

Feb 08 2022

• By Brenda Sandburg

Listen to this article

Sponsors are receiving information requests and complete response letters as a result of the agency’s transition plan, which was made in response to the Genus v. FDA ruling. The decision's aftershocks could reshape the landscape for a number of products, attorney says.

Seismic wave — Court ruling on drug-device classification has potential to be seismic event • Source: Alamy

The US Food and Drug Administration’s plan to transition certain products regulated as drugs to device status could have significant repercussions for the pharmaceutical industry. While the agency is focusing on whether imaging agents meet the device definition, it is also reexamining other product categories as well. Sponsors have already received complete response letters and notices of deficiencies in their applications as a result of the reclassification.

In August, the agency announced in a Federal Register notice that it would be publishing a list of approved drug...

More from Pink Sheet Perspectives

Nancy Tests Tableau for Bridget
Feb 04 2025
This is a short description.
Navigating The EU's Revised Clinical Trial Disclosure Rules
Feb 09 2024
• By Vibha Sharma
The European Medicines Agency is preparing to roll out simplified transparency rules for its Clinical Trials Information System in mid-2024. This article looks at what will change and the impact on the thousands of trials that are already in the system.
EU’s Innovative Drug Approval Tally Shows Sharp Decline
Jan 31 2024
• By Ian Schofield
The numbers may be down, but Europeans will in future be able to gain access to a number of highly innovative medicines, including several products for hard-to-treat cancers, a gene therapy for severe and moderately severe hemophilia B, and two vaccines against disease caused by respiratory syncytial virus.
As 2024 Begins, US FDA’s Novel Agent Prospects Look A Lot Like 2023
Jan 30 2024
• By Bridget Silverman
Immuno-oncology will remain a major force at both FDA’s drugs and biologics centers, but watch for psychiatry and antibiotics to make some noise; rare pediatric diseases will remain prominent as the priority review voucher program heads into the sunset.

More from Pink Sheet

Test FDA Voucher Program Approvals Will Come From Product Centers, But Ambiguity Lingers
Jan 23 2026
• By Sue Sutter
It is unclear in a revised staff manual guide whether Commissioner's National Priority Voucher program approval “recommendations” from the drug and biologic center directors will be advisory or decisional, experts told the Pink Sheet.
COVID Vaccines: US FDA Changes Course, Wants New Formulas To Target KP.2 Subvariant ‘If Feasible’
Jan 05 2026
• By Sue Sutter
Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’
Nancy Tests New Podcast Template
Dec 16 2025
• By Derrick Gingery
Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.